SoftOx Solutions AS: SOFTOX BIOFILM ERADICATOR STUDY (SBE-01) ADVANCES TO NEXT DOSE LEVEL DUE TO EXCELLENT SAFETY IN THE TREATMENT OF CHRONIC WOUNDS

SoftOx Solutions AS (SoftOx) are pleased to announce that the uptake of patients into the SBE-01 clinical study has improved considerably the past weeks, leading to completion of the first two dose-level cohorts. Due to lack of Serious Adverse Events / Adverse Events, the Safety Monitoring Committee were unanimous on escalation to the next dose-level. Although early in the study, we see that our solutions are well tolerated in chronic wounds and confirm so far what was documented in previous animal models, says Glenn Gundersen, Chief Medical Officer in SoftOx Solutions. SBE-01 (EudraCT no. 2021-000314-42) is the first-in-man (phase I) study with the SoftOx’ lead wound care product, SBE, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds. For further information, please contact: Geir Almås, CEO of SoftOx Solutions AS, or Glenn Gundersen, CMO SoftOx Solutions AS Mail: [email protected] Phone: Front Desk: (+47) 948-59-599 About SoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian BioTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com More information: Access the news on Oslo Bors NewsWeb site

The release as fetched from its publisher. soft-ox.com ↗